Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

doi:10.2217/fon-2017-0441

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

Future oncology (London, England) - 1 Feb 2018

Metro Giulio, Passaro Antonio, Lo Russo Giuseppe, Bonanno Laura, Giusti Raffaele, Gregorc Vanesa, Capelletto Enrica, Martelli Olga, Cecere Fabiana L, Giannarelli Diana, Luciani Andrea, Bearz Alessandra, Tuzi Alessandro, Scotti Vieri, Tonini Giuseppe, Galetta Domenico, Carta Annamaria, Soto Parra Hector, Rebonato Alberto, Morabito Alessandro, Chiari Rita

Abstract excerpt

AIM: Ceritinib was evaluated within a compassionate use program of Italian patients. PATIENTS & METHODS: 70 patients with anaplastic lymphoma kinase-positive crizotinib-refractory advanced non-small-cell lung cancer received ceritinib. RESULTS: Overall response was 40.6%, median progression-free survival was 8.2 months and median survival was 15.5 months. Dose reduction due to treatment-related adverse events...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crizotinib

Share to Gene Rearrangement

Share to Pyrazoles

Share to Pyridines

Share to Pyrimidines

Share to Receptor Protein-Tyrosine Kinases

Share to Sulfones

Source

Open in PubMed

Identifiers

PMID: 29135281
DOI: 10.2217/fon-2017-0441

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.PMID 29135281Read ↗

Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Cost effectiveness of ceritinib in patients previously treated with crizotinib and chemotherapy with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United StatesSemantic proximity Read ↗

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.Semantic proximity Read ↗

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.Semantic proximity Read ↗

Ceritinib for ALK-Rearranged Non–Small-Cell Lung CancerSemantic proximity Read ↗

Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase.Semantic proximity Read ↗

Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive Non-Small-Cell Lung CancerSemantic proximity Read ↗

Tumor growth inhibition modeling to support the starting dose for dacomitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.